OKYO Pharma Limited Directorate Change (3948X)
December 19 2019 - 1:00AM
UK Regulatory
TIDMOKYO
RNS Number : 3948X
OKYO Pharma Limited
19 December 2019
DIRECTORATE CHANGE
OKYO Pharma Limited ("OKYO" or the "Company") is pleased to
announces that Gregor MacRae has been appointed as a non-executive
director of the company with immediate effect. Leopoldo Zambeletti
is simultaneously standing down as a director of the Company with
immediate effect.
Gregor is a business adviser, who specialises in taxation and
cross border solutions. Presently, Gregor is the Senior Partner of
Appledore Wealth Management LLP which is a London-based high net
worth business advisory partnership. Previously, Gregor has been a
director of an international trust company (Vistra UK Limited,
formerly Chiltern Group Plc), which included holding the position
of managing director of the taxation and private client groups.
Gregor holds a degree in Law from University of Birmingham (LLB
Hons) and is a qualified Chartered Accountant (ICAEW).
Gregor will chair the Audit and Risk Committee of the Board
(which also comprises Willy Simon) and will sit as a member of the
Remuneration Committee (which also comprises Willy Simon as
chairman).
Willy Simon, Chairman of OKYO, said "We are delighted that
Gregor has joined the Board of OKYO. His expertise will be of great
value to us. He is a great addition to the Board at a very
important time for the group. I thank Leopoldo for his contribution
to the Board and the Company and wish him well in his other
interests".
Gregor is also a director of B C Estate Limited and senior
partner of Appledore Wealth Management LLP. Save as disclosed
herein, there are no further details required to be disclosed
pursuant to Listing Rule 9.6.13 in connection with Gregor's
appointment.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7382 8300
Antonio Bossi
Shore Capital Limited (Broker) David Coaten +44 (0)20 7601 6100
-------------- -------------------
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAZMMMZNRDGLZM
(END) Dow Jones Newswires
December 19, 2019 02:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024